Major US bank shoots way above Novo Nordisk's own goals: New obesity drug will sell for almost USD 3.5bn in 2025.
US banking giant J.P. Morgan forecasts that Novo Nordisk will have increased its obesity business more than fourfold by 2025. Novo Nordisk aspires to more than double the business leg.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk's aspirations to more than double its obesity business by 2025 is way off the mark, according to major US bank J.P. Morgan.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades guidance for the rest of the year
For subscribers
